Blinatumomab Has Activity in Patients with TKI-Refractory Ph+ ALL [Structural Biology]

Blinatumomab achieved complete remission with full or partial hematologic recovery in 36% of patients.
Source: Cancer Discovery - Category: Cancer & Oncology Tags: Structural Biology Source Type: research